Replies to post #683677 on NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

Pseudo is temporary and was accounted for in post trial results. Placebo had better results in PFS , as pointed out in one of my previous posts...

The authors state that the PFS endpoint became infeasible because of pseudo-progression issues, however, to the best of our knowledge in no other study that issue has resulted in abandoning the primary endpoint. Fortunately, the numerical PFS data are now presented: ****the median PFS was 6.2 (95% confidence interval CI 5.7–7.4) months for patients receiving DCVax-L and 7.6 (95% CI 5.6–10.9) months for the placebo group****